ArticleNature2017
Blocking FSH induces thermogenic adipose tissue and reduces body fat.
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 220 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
220 citing papers in PubMed, 2 syntheses or guidelines pooled it, 341 citations in OpenAlex.
- Comparison of efficacy of acupuncture-related therapy in the treatment of perimenopausal obesity: a network meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Prevalence of sarcopenic obesity in the older non-hospitalized population: a systematic review and meta-analysis.BMC geriatrics · 2024Pooled it
- Trial
- High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women.Frontiers in endocrinology · 2021Trial
- A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free-Living Energy Expenditure.Obesity (Silver Spring, Md.) · 2020Trial
- Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Trial
- Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review.Women's health nursing (Seoul, Korea) · 2026Review
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- The extragonadal biology of gonadotropin hormones: should we rename these?Endocrine connections · 2026Article
- "One-stop-shop" medical imaging for osteoporosis and obese patients: a narrative review.Journal of endocrinological investigation · 2026Review
- Sex differences in response to longevity interventions.Ageing research reviews · 2026Review
- Clinical review: Menopause hormone therapy in weight management.Obesity pillars · 2026Review
- Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes.Antioxidants (Basel, Switzerland) · 2026Review
- Neuroendocrine and neural control of bone mass in health and disease.The Journal of clinical investigation · 2026Review
- Optimal visceral adipose tissue thresholds that minimize risk for osteoporosis and/or diabetes in midlife women.Journal of the Endocrine Society · 2026Article
- Fshr gene depletion prevents recognition memory loss, fat accrual and bone loss in Alzheimer's mice.Molecular psychiatry · 2026Article
- Reduction of glycation stress as a geroscience intervention: protocol for a pilot RCT in postmenopausal women.npj aging · 2026Article
- Follicle-Stimulating Hormone in Peripheral Metabolism: Novel Insights into Growth Regulation and Potential Applications in Boar Production.Animals : an open access journal from MDPI · 2026Review
- C/EBPβ dictates postmenopausal FSHβ transcription and blockade of AEP/C/EBPβ pathway alleviates osteoporosis.Bone research · 2026Article
- FSH Signaling in Osteoporosis and Alzheimer's Disease.Current osteoporosis reports · 2026Review
160 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
40 authors at 10 institutions in 4 countries.
Funding
Abstract
Menopause is associated with bone loss and enhanced visceral adiposity. A polyclonal antibody that targets the β-subunit of the pituitary hormone follicle-stimulating hormone (Fsh) increases bone mass in mice. Here, we report that this antibody sharply reduces adipose tissue in wild-type mice, phenocopying genetic haploinsufficiency for the Fsh receptor gene Fshr. The antibody also causes profound beiging, increases cellular mitochondrial density, activates brown adipose tissue and enhances thermogenesis. These actions result from the specific binding of the antibody to the β-subunit of Fsh to block its action. Our studies uncover opportunities for simultaneously treating obesity and osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.